Predictive Oncology (NASDAQ:AGPU) Stock Rating Lowered by Wall Street Zen

Predictive Oncology (NASDAQ:AGPU) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Sunday.

Separately, Weiss Ratings upgraded shares of Predictive Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 1st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

Predictive Oncology Stock Performance

Shares of Predictive Oncology stock opened at $7.12 on Friday. The firm’s fifty day moving average is $6.10. The stock has a market cap of $77.04 million, a P/E ratio of -0.87 and a beta of 3.47. Predictive Oncology has a 12-month low of $1.03 and a 12-month high of $32.10.

Predictive Oncology (NASDAQ:AGPU) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.36) EPS for the quarter. Predictive Oncology had a negative return on equity of 7,363.67% and a negative net margin of 470,383.31%.The company had revenue of $0.04 million during the quarter.

About Predictive Oncology

Predictive Oncology (NASDAQ: AGPU) is a biotechnology company focused on oncology-related research and product development that combines laboratory science with data analytics. The company positions itself to support precision medicine by applying computational methods and laboratory testing to better understand tumor biology and to accelerate the identification and development of oncology therapeutics and diagnostics.

Its activities include laboratory-based testing and analytic services intended to inform drug discovery and development, biomarker identification, and patient stratification efforts.